Evidence map›Paper›PMID 30106842›Full record

ArticleMelanoma research2020

Stage-specific incidence trends of melanoma in an English region, 1996-2015: longitudinal analyses of population-based data.

Annie Herbert, Minjoung M Koo, Matthew E Barclay, David C Greenberg, Gary A Abel, Nick J Levell, Georgios Lyratzopoulos

Open access · hybridAbstract read
In one paragraph

Article in Melanoma research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Cancer overdiagnosis: a challenge in the era of screening.Journal of the National Cancer Center · 2022
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Trends in Incidence and Mortality of Skin Melanoma in Lithuania 1991-2015.International journal of environmental research and public health · 2021
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Annie HerbertDepartment of Behavioural Sciences and Health, Epidemiology of Cancer Healthcare and Outcomes Research Group, University College London, London.
Minjoung M KooDepartment of Behavioural Sciences and Health, Epidemiology of Cancer Healthcare and Outcomes Research Group, University College London, London.
Matthew E BarclayPublic Health England National Cancer Registration and Analysis Service, Fulbourn.
David C GreenbergPublic Health England National Cancer Registration and Analysis Service, Fulbourn.
Gary A AbelPrimary Care, University of Exeter Medical School, Exeter.
Nick J LevellDepartment of Dermatology, Norfolk and Norwich University Hospital, Norwich, UK.
Georgios LyratzopoulosDepartment of Behavioural Sciences and Health, Epidemiology of Cancer Healthcare and Outcomes Research Group, University College London, London.
University College London · GBPublic Health England · GBNorfolk and Norwich University Hospital · GBUniversity of Exeter · GB

Funding

Cancer Research UK 18180Cancer Research UK C18081/A18180Cancer Research UK C8640/A23385
6 · The paper itself

Abstract

The aim of this study was to examine temporal trends in overall and stage-specific incidence of melanoma. Using population-based data on patients diagnosed with melanoma in East Anglia, England, 1996-2015, we estimated age-standardized time trends in annual incidence rates for each stage at diagnosis. Negative binomial regression was used to model trends over time adjusted for sex, age group and deprivation, and to subsequently examine variation in stage-specific trends by sex and age group. The age-standardized incidence increased from 14 to 29 cases/100 000 persons (i.e. 4% annually). Increasing incidence was apparent across all stages but was steepest for stage I [adjusted annual increase: 5%, 95% confidence interval (CI): 5-6%, and more gradual for stage II-IV disease (stage II: 3%, 95% CI: 2-4%; stage III/IV: 2%, 95% CI: 1-3%)]. Stage II-IV increase was apparent in men across age groups and in women aged 50 years or older. Increases in incidence were steeper in those aged 70 years or older, and in men. The findings suggest that both a genuine increase in the incidence of consequential illness and a degree of overdiagnosis may be responsible for the observed increasing incidence trends in melanoma in our population during the study period. They also suggest the potentially lower effectiveness of public health awareness campaigns in men and older people.

Indexed as

AdolescentAdultAgedAged, 80 and overEnglandFemaleHumansIncidenceLongitudinal StudiesMaleMelanomaMiddle AgedSkin NeoplasmsYoung Adult

Identifiers

PMID30106842
PMCPMC6330074
OpenAlexW2885924088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.